Sarah Howell, Ph.D., Chief Executive Officer
Sarah, who joined Arecor in 2011, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.
Susan Lowther, Chief Financial Officer and Company Secretary
Susan joined Arecor in 2019 as Chief Financial Officer and Company Secretary. She has significant experience of the life science industry, growing companies and executing M&A transactions. She also has a strong commercial and operational background, with direct responsibility for finance, HR, IT and facilities functions.
Jan Jezek, Ph.D., Chief Scientific Officer
Jan is a biochemist with a strong background in physical chemistry and the principal inventor of the core protein stabilisation technologies. He is responsible at Arecor for R&D activities, platform development and IP strategy. He played a critical role in the development of stabilising technologies for commercially important therapeutic proteins and vaccines that form the core of Arecor business.
David Gerring, VP, Development
David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.
Fiona Lawrence, VP, Clinical & Regulatory Affairs and QA
Fiona is a pharmaceutical research and development professional and is VP, Clinical & Regulatory Affairs and QA at Arecor, where she has responsibility for driving the clinical development of Arecor’s proprietary products’ portfolio.
Jim MacDonald-Clink, VP, Business Development
Jim joined Arecor in November 2019 as VP, Business Development. Jim previously worked at Mundipharma, where he was responsible for Business Development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements. His experience includes acquisition, licensing and strategic partnering initiatives in specialist therapy areas as well as various roles in R&D, Medical and Commercial functions. Jim has over 25 years of experience in healthcare with Mundipharma, Astellas Pharma, Fujisawa, Institute of Cancer Research at the Royal Marsden and Institute of Child Health at Great Ormond Street Hospital, London, UK.